Serous Adenocarcinoma — Trials

Serous Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 85
Recruiting: 35
Ph III recruiting: 6
Growth YoY: —
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04159155	A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP)	terminated	Phase 2 / Phase 3	11	University Health Network, TorontoOTHER	1	Aug 12, 2025	clinicaltrials
NCT01849874	A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer	terminated	Phase 3	341	PfizerINDUSTRY	19	Oct 30, 2023